

27th April, 2018

BSE Limited
24th Floor, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir,

Kind Attn.: Mr. Subhash Purohit

Sub: Clarification on news item appeared in “MINT”

This refers to your E-mail dated 27th April, 2018 regarding the news item appeared in newspaper MINT (Source: www.livemint.com)

In this regard, we have to inform you that Wockhardt Limited ('the Company') was neither a manufacturer nor an importer nor a marketer for “Methyldopa 250 mg”.

However, Department of Pharmaceuticals ('DoP') has twice passed order in favour of the Company in relation to price fixation of “Methyldopa 500 mg” that is manufactured and marketed by the Company.

In the last review application filed by the Company, the DoP has ordered National Pharmaceutical Pricing Authority ('NPPA') to refix price of “Methyldopa 500 mg” as per paras 4 (1) and 6 of the DPCO, 2013. The matter is pending with NPPA as on date.

Please note that the Company is selling the product “Methyldopa 500 mg” in small quantities in domestic market.

Kindly take the same on your records.

For **Wockhardt Limited**



Narendra Singh
Company Secretary

